<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40402499</article-id><article-id pub-id-type="pmc">PMC12100447</article-id>
<article-id pub-id-type="doi">10.1001/jamanetworkopen.2025.12139</article-id><article-id pub-id-type="publisher-id">zld250070</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Neurology</subject></subj-group></article-categories><title-group><article-title>Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During Spermatogenesis</article-title><alt-title alt-title-type="headline">Risk of Neurodevelopmental Disorders and Paternal Use of Valproate</alt-title><alt-title alt-title-type="running-head">Risk of Neurodevelopmental Disorders and Paternal Use of Valproate</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Christensen</surname><given-names>Jakob</given-names></name><degrees>DrMedSci</degrees><xref rid="zld250070aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zld250070aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Trabjerg</surname><given-names>Betina B.</given-names></name><degrees>MSc</degrees><xref rid="zld250070aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zld250070aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dreier</surname><given-names>Julie Werenberg</given-names></name><degrees>PhD</degrees><xref rid="zld250070aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="zld250070aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="zld250070aff1"><label>1</label>Department of Clinical Medicine, Aarhus University, Aarhus, Denmark</aff><aff id="zld250070aff2"><label>2</label>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark</aff><aff id="zld250070aff3"><label>3</label>National Centre for Register-Based Research, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark</aff><aff id="zld250070aff4"><label>4</label>Centre for Integrated Register-Based Research (CIRRAU), Aarhus University, Aarhus, Denmark</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> March 24, 2025.</p><p content-type="published-online"><bold>Published:</bold> May 22, 2025. doi:<uri content-type="doi">10.1001/jamanetworkopen.2025.12139</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#x000a9; 2025 Christensen J et al. <italic>JAMA Network Open</italic>.</p><corresp id="zld250070cor1"><bold>Corresponding Author:</bold> Jakob Christensen, DrMedSci, Department of Neurology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, DK-8200 Aarhus N, Denmark (<email xlink:href="jakob@farm.au.dk">jakob@farm.au.dk</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Ms Trabjerg had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic>Concept and design:</italic> Christensen, Dreier.</p><p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p><p><italic>Drafting of the manuscript:</italic> Christensen, Trabjerg.</p><p><italic>Critical review of the manuscript for important intellectual content:</italic> Christensen, Dreier.</p><p><italic>Statistical analysis</italic>: Christensen, Trabjerg.</p><p><italic>Obtained funding:</italic> Christensen, Dreier.</p><p><italic>Administrative, technical, or material support</italic>: Christensen, Dreier.</p><p><italic>Supervision:</italic> All authors.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Christensen reported receiving honoraria from giving lectures to and serving on the scientific advisory board of and giving lectures UCB Nordic and Eisai AB, and funding for a trip from UCB Nordic. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> The study was supported by the Independent Research Fund Denmark (grant No. 1133-00026B), the Danish Epilepsy Association, the Central Denmark Region, the Novo Nordisk Foundation (grant Nos. NNF16OC0019126 and NNF22OC0075033), and the Lundbeck Foundation (grant No. R400-2022-1205).</p><p><bold>Role of the Funder/Sponsor:</bold> The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZLD250070-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-05-22T10:00"><day>22</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>8</volume><issue>5</issue><elocation-id>e2512139</elocation-id><history><date date-type="received"><day>6</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright 2025 Christensen J et al. <italic>JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2512139.pdf">jamanetwopen-e2512139.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.12139"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cohort study assesses associations of paternal use of valproate with neurodevelopmental disorders in children.</p></abstract></article-meta></front><body><sec id="H1-1-ZLD250070"><title>Introduction</title><p>In January 2024, the European Medicines Agency (EMA) recommended precautionary measures for the treatment of male patients with valproate.<sup><xref rid="zld250070r1" ref-type="bibr">1</xref></sup> This followed an observational study report prepared by the contract research organization IQVIA, reporting a potential risk of neurodevelopmental disorders (NDDs) in children born to males treated with valproate during spermatogenesis.<sup><xref rid="zld250070r1" ref-type="bibr">1</xref>,<xref rid="zld250070r2" ref-type="bibr">2</xref></sup> In a subsequent study based on a subset of the same data, we were unable to replicate the IQVIA study results.<sup><xref rid="zld250070r3" ref-type="bibr">3</xref></sup> However, at the time when our study was accepted for publication (March 31, 2024), limited information was available about the IQVIA study, and a detailed online report was only published on May 17, 2024.<sup><xref rid="zld250070r4" ref-type="bibr">4</xref></sup> To address the conflicting results between the 2 studies,<sup><xref rid="zld250070r3" ref-type="bibr">3</xref>,<xref rid="zld250070r2" ref-type="bibr">2</xref></sup> we present additional analyses of our data material with further alignments to the IQVIA study.<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup></p></sec><sec id="H1-2-ZLD250070"><title>Methods</title><p>This cohort study was approved by the Danish Data Protection Agency and did not require ethical review board approval or informed consent according to Danish law. The reporting followed the <ext-link xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link> guideline. We identified all singleton children born alive in Denmark between 1997 and 2017. We excluded children of mothers who had undergone in vitro fertilization, with unknown or unrealistic gestational age, and without paternal link (98&#x02009;670 children), leaving a population of 1&#x02009;180&#x02009;308 children. Paternal monotherapy exposure to valproate, lamotrigine, and levetiracetam was defined as filling 1 or more prescriptions for only 1 of these medications from 120 days before the first day of the last menstrual period (LMP) to 14 days after the LMP. Additionally, we conducted a sensitivity analysis with a restricted exposure window from 60 days before to 14 days after the LMP. Children were followed-up from age 1 year until December 31, 2018, for diagnoses of NDDs. We used Cox regression to estimate adjusted hazard ratios (aHRs) of NDDs comparing children exposed to valproate monotherapy with children exposed to lamotrigine or levetiracetam monotherapy, adjusted for relevant confounders (eTables 1-5 in <xref rid="note-ZLD250070-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zld250070r3" ref-type="bibr">3</xref></sup> A range of analyses were performed to explore the impact of methodological choices and definitions used in the IQVIA study<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup>: excluding children of parents with NDDs or congenital malformations, excluding children of mothers with epilepsy; excluding children with epilepsy, rerunning analyses without adjustment for parental epilepsy and education, and stopping follow-up at age 12 years. Data were analyzed in February 2025 using SAS version 9.4 (SAS Institute). Statistical significance was a 2-sided <italic>P</italic>&#x02009;&#x0003c;&#x02009;.05.</p></sec><sec id="H1-3-ZLD250070"><title>Results</title><p>In the overall analysis based on 961 children (501 male [52.1%]; median [IQR] age at the end of follow-up, 10.6 [5.4-15.0] years) exposed to valproate monotherapy and 1401 children (725 male [51.8%]; median [IQR] age at end of follow-up, 5.5 [2.7-9.3] years) exposed to lamotrigine or levetiracetam monotherapy, paternal valproate exposure was not associated with an increased risk of NDDs (composite end point of all NDD aHR, 1.02; 95% CI, 0.67-1.54). This finding remained robust across analyses of specific NDDs, analyses of valproate dose, analyses accounting for time trends, analyses allowing for polytherapy, analyses expanding the definition of NDDs, analyses restricted to fathers with epilepsy, and analyses with a restricted exposure window (<xref rid="zld250070t1" ref-type="table">Table 1</xref>). In analyses restricted to fathers with epilepsy of unknown underlying cause, the aHR was 2.48 (95% CI, 1.13-5.44)<sup><xref rid="zld250070r5" ref-type="bibr">5</xref></sup>; however, the association was no longer significant in analyses matched on birth year (aHR, 2.33; 95% CI, 1.00-5.44). Analyses undertaken to further examine the definitions used in the IQVIA study<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup> revealed no increased risk of NND associated with valproate exposure (<xref rid="zld250070t2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="zld250070t1"><label>Table 1. </label><caption><title>Risk of NDDs in Children of Fathers Who Used Valproate Compared With Children of Fathers Who Used Lamotrigine or Levetiracetam During Spermatogenesis</title></caption><table frame="hsides" rules="groups"><col width="40.35%" span="1"/><col width="7.02%" span="1"/><col width="12.28%" span="1"/><col width="6.14%" span="1"/><col width="6.14%" span="1"/><col width="13.16%" span="1"/><col width="14.91%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Analysis and comparison groups</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Exposed, No.</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Follow-up time, median (IQR), y</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">NDD cases, No.</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">IR/1000 person-years</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Risk of NDD, HR (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unadjusted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Main analysis</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Composite end point of all NDDs<xref rid="zld250070t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="top" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="top" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (5.4-15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.68-1.44)</td><td valign="top" align="left" rowspan="1" colspan="1">1.02 (0.67-1.54)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Intellectual disability<xref rid="zld250070t1n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.6 (2.7-9.5)</td><td valign="middle" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="top" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">11.1 (5.8-15.4)</td><td valign="middle" align="left" rowspan="1" colspan="1">21</td><td valign="top" align="left" rowspan="1" colspan="1">2.1</td><td valign="top" align="left" rowspan="1" colspan="1">2.29 (0.96-5.46)</td><td valign="top" align="left" rowspan="1" colspan="1">1.85 (0.72-4.76)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Disorders of psychological development<xref rid="zld250070t1n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="top" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">1.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="top" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">11.2 (5.7-15.5)</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1.4</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.45-2.25)</td><td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.38-2.24)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Autism spectrum disorder<xref rid="zld250070t1n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="top" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">3.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">11.1 (5.7-15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">2.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.31-0.93)</td><td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.37-1.28)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> ADHD<xref rid="zld250070t1n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">3.0</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (5.6-15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">2.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.40-1.19)</td><td valign="top" align="left" rowspan="1" colspan="1">0.60 (0.33-1.12)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Secondary analyses</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High dose</td><td valign="middle" align="left" rowspan="1" colspan="1">490</td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (6.4-15.4)</td><td valign="middle" align="left" rowspan="1" colspan="1">33</td><td valign="top" align="left" rowspan="1" colspan="1">6.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.92 (0.59-1.43)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.61-1.63)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Low dose</td><td valign="middle" align="left" rowspan="1" colspan="1">471</td><td valign="top" align="left" rowspan="1" colspan="1">10.1 (4.6-14.6)</td><td valign="middle" align="left" rowspan="1" colspan="1">34</td><td valign="top" align="left" rowspan="1" colspan="1">7.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.08 (0.69-1.68)</td><td valign="top" align="left" rowspan="1" colspan="1">1.04 (0.64-1.67)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Accounting for calendar trends (matched on birth year)<xref rid="zld250070t1n6" ref-type="table-fn"><sup>f</sup></xref></td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">715</td><td valign="top" align="left" rowspan="1" colspan="1">8.4 (4.2-12.1)</td><td valign="middle" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="left" rowspan="1" colspan="1">6.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">715</td><td valign="top" align="left" rowspan="1" colspan="1">8.3 (4.2-11.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="left" rowspan="1" colspan="1">7.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.07 (0.69-1.65)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (0.68-1.75)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Allowing for polytherapy and monotherapy in both groups<xref rid="zld250070t1n7" ref-type="table-fn"><sup>g</sup></xref></td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1710</td><td valign="top" align="left" rowspan="1" colspan="1">6.0 (2.8-10.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">1252</td><td valign="top" align="left" rowspan="1" colspan="1">10.4 (5.3-14.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">84</td><td valign="top" align="left" rowspan="1" colspan="1">6.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.01 (0.73-1.41)</td><td valign="top" align="left" rowspan="1" colspan="1">1.06 (0.74-1.50)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Including ADHD medication in definition of NDD</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.4 (2.7-9.2)</td><td valign="middle" align="left" rowspan="1" colspan="1">55</td><td valign="top" align="left" rowspan="1" colspan="1">6.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.5 (5.4-15.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">72</td><td valign="top" align="left" rowspan="1" colspan="1">7.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.68-1.40)</td><td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.66-1.45)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Restricted to fathers with epilepsy</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">737</td><td valign="top" align="left" rowspan="1" colspan="1">6.4 (3.0-10.7)</td><td valign="middle" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">3.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">740</td><td valign="top" align="left" rowspan="1" colspan="1">10.9 (6.4-15.1)</td><td valign="middle" align="left" rowspan="1" colspan="1">56</td><td valign="top" align="left" rowspan="1" colspan="1">7.1</td><td valign="top" align="left" rowspan="1" colspan="1">1.60 (0.96-2.69)</td><td valign="top" align="left" rowspan="1" colspan="1">1.42 (0.82-2.46)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Restricted to fathers with epilepsy, matched on birth year</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">511</td><td valign="top" align="left" rowspan="1" colspan="1">8.5 (4.7-12.1)</td><td valign="middle" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t1n8" ref-type="table-fn"><sup>h</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">4.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">511</td><td valign="top" align="left" rowspan="1" colspan="1">8.5 (4.5-12.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">5.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.42 (0.76-2.64)</td><td valign="top" align="left" rowspan="1" colspan="1">1.14 (0.59-2.21)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Restricted to fathers with epilepsy of unknown underlying cause</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">478</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (3.3-11.2)</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2.2</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">593</td><td valign="top" align="left" rowspan="1" colspan="1">11.4 (6.9-15.4)</td><td valign="middle" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">7.7</td><td valign="top" align="left" rowspan="1" colspan="1">3.04 (1.43-6.44)</td><td valign="top" align="left" rowspan="1" colspan="1">2.48 (1.13-5.44)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Restricted to fathers with epilepsy of unknown underlying cause, matched on birth year</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">362</td><td valign="top" align="left" rowspan="1" colspan="1">8.5 (4.5-12.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">2.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">362</td><td valign="top" align="left" rowspan="1" colspan="1">8.2 (4.4-11.9)</td><td valign="middle" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">7.1</td><td valign="top" align="left" rowspan="1" colspan="1">3.09 (1.39-6.89)</td><td valign="top" align="left" rowspan="1" colspan="1">2.33 (1.00-5.44)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ADHD, attention-deficit/hyperactivity disorder; HR, hazard ratio; IR, incidence rate; NA, not applicable; NDD, neurodevelopmental disorder.</p><fn id="zld250070t1n1"><label>
<sup>a</sup>
</label><p>In sensitivity analysis with a restricted exposure window from 60 days before to 14 after the first day of the last menstrual period, valproate exposure was not associated with NDD risk (adjusted HR [aHR], 0.96; 95% CI, 0.62-1.49). In analyses with follow-up time split in 2 periods, valproate exposure was not associated with NDD risk in either early (aHR, 1.30; 95% CI, 0.66-2.57) or late (aHR, 0.89; 95% CI, 0.52-1.50) follow-up periods.</p></fn><fn id="zld250070t1n2"><label>
<sup>b</sup>
</label><p><italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) </italic>codes F70-79.</p></fn><fn id="zld250070t1n3"><label>
<sup>c</sup>
</label><p><italic>ICD-10</italic> codes F80-83.</p></fn><fn id="zld250070t1n4"><label>
<sup>d</sup>
</label><p><italic>ICD-10</italic> code F84 (excluding F84.2-F84.4).</p></fn><fn id="zld250070t1n5"><label>
<sup>e</sup>
</label><p><italic>ICD-10</italic> codes F90.0 and F98.8.</p></fn><fn id="zld250070t1n6"><label>
<sup>f</sup>
</label><p>Equal number of exposed and unexposed per birth year.</p></fn><fn id="zld250070t1n7"><label>
<sup>g</sup>
</label><p>Children where the father filled prescriptions for valproate in combination with lamotrigine and/or levetiracetam were only included in the valproate group.</p></fn><fn id="zld250070t1n8"><label>
<sup>h</sup>
</label><p>Differences less than 5 cannot be reported for data privacy reasons.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="zld250070t2"><label>Table 2. </label><caption><title>Analyses Undertaken to Examine Definitions Used in the IQVIA Study<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup></title></caption><table frame="hsides" rules="groups"><col width="36.85%" span="1"/><col width="7.89%" span="1"/><col width="14.92%" span="1"/><col width="6.14%" span="1"/><col width="7.89%" span="1"/><col width="13.16%" span="1"/><col width="13.15%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Comparison</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Exposed, No.</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Follow-up time, median (IQR), y</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">NDD cases, No.</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1">IR/1000 person-years</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Risk of NDD, HR (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Unadjusted</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Adjusted</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Main analysis<xref rid="zld250070t2n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="middle" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (5.4-15.0)</td><td valign="middle" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.68-1.44)</td><td valign="top" align="left" rowspan="1" colspan="1">1.02 (0.67-1.54)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Secondary analyses</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Excluding children of parents with malformations or NDDs<xref rid="zld250070t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1274</td><td valign="top" align="left" rowspan="1" colspan="1">5.7 (2.8-9.5)</td><td valign="top" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">902</td><td valign="top" align="left" rowspan="1" colspan="1">11.1 (6.0-15.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.66-1.42)</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.64-1.52)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Excluding children of mothers with epilepsy<xref rid="zld250070t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1373</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">931</td><td valign="top" align="left" rowspan="1" colspan="1">10.7 (5.5-15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">6.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.65-1.39)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.64-1.49)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Excluding children with epilepsy<xref rid="zld250070t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1380</td><td valign="top" align="left" rowspan="1" colspan="1">5.43 (2.6-9.2)</td><td valign="top" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">924</td><td valign="top" align="left" rowspan="1" colspan="1">10.5 (5.3-15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">59</td><td valign="top" align="left" rowspan="1" colspan="1">6.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.93 (0.63-1.37)</td><td valign="top" align="left" rowspan="1" colspan="1">0.98 (0.63-1.51)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Leaving out adjustment for maternal and paternal epilepsy</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (5.4-15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">0.99 (0.65-1.49)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Leaving out adjustment for maternal and paternal education</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">50</td><td valign="top" align="left" rowspan="1" colspan="1">5.6</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (5.4-15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">67</td><td valign="top" align="left" rowspan="1" colspan="1">6.7</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (0.73-1.67)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Ending follow-up at 12 y</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lamotrigine or levetiracetam</td><td valign="middle" align="left" rowspan="1" colspan="1">1401</td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (2.7-9.3)</td><td valign="top" align="left" rowspan="1" colspan="1">NA<xref rid="zld250070t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.8</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td><td valign="top" align="left" rowspan="1" colspan="1">1.00 [Reference]</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Valproate</td><td valign="middle" align="left" rowspan="1" colspan="1">961</td><td valign="top" align="left" rowspan="1" colspan="1">10.6 (5.4-11.0)</td><td valign="top" align="left" rowspan="1" colspan="1">45</td><td valign="top" align="left" rowspan="1" colspan="1">5.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.84 (0.56-1.27)</td><td valign="top" align="left" rowspan="1" colspan="1">0.85 (0.53-1.36)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: HR, hazard ratio; IR, incidence rate; NA, not applicable; NDD, neurodevelopmental disorder.</p><fn id="zld250070t2n1"><label>
<sup>a</sup>
</label><p>Analysis using Cox proportional hazards regression comparing children of fathers exposed to valproate in monotherapy with children of fathers exposed to lamotrigine or levetiracetam in monotherapy, with unadjusted HRs and HRs adjusting for sex of the child, year of birth, paternal and maternal characteristics (age, psychiatric diagnoses, psychotropic medication use, epilepsy diagnosis, and educational level), and maternal valproate use during pregnancy.</p></fn><fn id="zld250070t2n2"><label>
<sup>b</sup>
</label><p>Children were excluded if the parents had an NDD or congenital malformation diagnosis before 120 days before the first day of the last menstrual period.</p></fn><fn id="zld250070t2n3"><label>
<sup>c</sup>
</label><p>Numbers are not shown because the differences from the numbers in the main analysis are less than 5.</p></fn><fn id="zld250070t2n4"><label>
<sup>d</sup>
</label><p>Children were excluded if the mother had an epilepsy diagnosis before 120 days before the first day of the last menstrual period.</p></fn><fn id="zld250070t2n5"><label>
<sup>e</sup>
</label><p>Children were excluded if they received an epilepsy diagnosis or had filled a prescription for antiseizure medication at any point during follow-up.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-ZLD250070"><title>Discussion</title><p>Despite our additional alignments of the study population and definitions to the IQVIA study report,<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup> this cohort study was unable to replicate the signal for NDDs in children with paternal valproate exposure. Instead, findings from these additional analyses are in line with our initial study<sup><xref rid="zld250070r3" ref-type="bibr">3</xref></sup> and the conclusions of a recent systematic review,<sup><xref rid="zld250070r6" ref-type="bibr">6</xref></sup> suggesting that paternal exposure to antiseizure medication in association with conception is unlikely to pose any major risk for the offspring. Although our study was large, it has limitations inherent to observational investigations based on register data.<sup><xref rid="zld250070r3" ref-type="bibr">3</xref></sup> Given the potentially substantial implications of the EMA recommendation<sup><xref rid="zld250070r1" ref-type="bibr">1</xref></sup> and the lack of reproducibility of the signal from the IQVIA study,<sup><xref rid="zld250070r2" ref-type="bibr">2</xref></sup> we strongly urge for full transparency, including publication of the analytical code and full peer-review of the IQVIA study as soon as possible.</p></sec></body><back><ref-list id="REF-ZLD250070"><title>References</title><ref id="zld250070r1"><label>1</label><mixed-citation publication-type="webpage">European Medicines Agency Safety Committee. Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. Published January 12, 2024. Accessed April 17, 2025. <ext-link xlink:href="https://www.ema.europa.eu/en/news/potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines-prac-recommends-precautionary-measures" ext-link-type="uri">https://www.ema.europa.eu/en/news/potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines-prac-recommends-precautionary-measures</ext-link></mixed-citation></ref><ref id="zld250070r2"><label>2</label><mixed-citation publication-type="webpage"><person-group><collab>IQVIA</collab></person-group>. A post-authorisation safety study (PASS) to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring&#x02014;a population-based retrospective study. Published March 20, 2023. Accessed April 17, 2025. <ext-link xlink:href="https://www.ema.europa.eu/en/documents/other/valproate-paternal-exposure-valproate-final-report_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/other/valproate-paternal-exposure-valproate-final-report_en.pdf</ext-link></mixed-citation></ref><ref id="zld250070r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Christensen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Trabjerg</surname>
<given-names>BB</given-names></string-name>, <string-name><surname>Dreier</surname>
<given-names>JW</given-names></string-name></person-group>. <article-title>Valproate use during spermatogenesis and risk to offspring</article-title>. <source>JAMA Netw Open</source>. <year>2024</year>;<volume>7</volume>(<issue>6</issue>):<elocation-id>e2414709</elocation-id>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2024.14709</pub-id><pub-id pub-id-type="pmid">38833248</pub-id>
</mixed-citation></ref><ref id="zld250070r4"><label>4</label><mixed-citation publication-type="webpage"><person-group><collab>European Medicines Agency</collab></person-group>. Outcomes of imposed non-interventional post-authorisation safety studies. Accessed April 17, 2025. <ext-link xlink:href="https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/post-authorisation-safety-studies-pass/outcomes-imposed-non-interventional-post-authorisation-safety-studies" ext-link-type="uri">https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/post-authorisation-safety-studies-pass/outcomes-imposed-non-interventional-post-authorisation-safety-studies</ext-link></mixed-citation></ref><ref id="zld250070r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Christensen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Trabjerg</surname>
<given-names>BB</given-names></string-name>, <string-name><surname>Wagner</surname>
<given-names>RG</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence of epilepsy: a population-based cohort study in Denmark with comparison to global burden of disease (GBD) prevalence estimates</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2025</year>;<volume>96</volume>(<issue>5</issue>):<fpage>480</fpage>-<lpage>488</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2024-334547</pub-id><pub-id pub-id-type="pmid">39532519</pub-id>
</mixed-citation></ref><ref id="zld250070r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Honybun</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rayner</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Malpas</surname>
<given-names>CB</given-names></string-name>, <etal/></person-group>. <article-title>Paternal exposure to antiseizure medications and offspring outcomes: a systematic review</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2024</year>;<volume>96</volume>(<issue>1</issue>):<fpage>15</fpage>-<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2024-334077</pub-id><pub-id pub-id-type="pmid">39299778</pub-id>
</mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZLD250070-1"><supplementary-material id="note-ZLD250070-1-s" position="float" content-type="local-data"><label>Supplement 1.</label><caption><p><bold>eTable 1.</bold> Variable Definitions</p><p><bold>eTable 2.</bold> Outcome Definitions in Children Diagnosed With Neurodevelopmental Disorders According to <italic>ICD-10</italic> and Filling for Prescriptions for Attention-Deficit/Hyperactivity Disorder (ADHD) Medication According to Anatomical Therapeutic Chemical Code (ATC Codes)</p><p><bold>eTable 3.</bold> Diagnostic Classification of Underlying Causes of Epilepsy (&#x0201c;Secondary Epilepsy&#x0201d;) According to <italic>ICD-10</italic> and Equivalent <italic>ICD-8</italic> Diagnoses</p><p><bold>eTable 4.</bold>
<italic>ICD-10</italic> Codes Used for the Identification of Major Congenital Malformations</p><p><bold>eTable 5.</bold> Additional Description for Table 1</p><p>
eReferences.
</p></caption><media xlink:href="jamanetwopen-e2512139-s001.pdf"/></supplementary-material><supplementary-material position="float" content-type="local-data"><label>Supplement 2.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamanetwopen-e2512139-s002.pdf"/></supplementary-material></notes></back></article><!--requester-ID cbaker-->